Introduction
============

The vitamin D~3~ receptor (VDR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and was first identified as a key player maintaining calcium and phosphate homeostasis \[[@b1]\]. VDR is activated upon binding of its ligand calcitriol (1,25(OH)~2~ vitamin D~3~, throughout the text referred to as 'vitamin D~3~'). This leads to homodimerization of VDR or heterodimerization with other nuclear receptors, binding to vitamin D~3~ responsive elements (VDREs) and activation of the transcription of VDR target genes \[[@b2]--[@b5]\].

There is accumulating evidence that actions of VDR are not confined to processes related to calcium homeostasis and skeletal development, but extend to cell survival, differentiation \[[@b6], [@b7]\], proliferation \[[@b8], [@b9]\] and cell death \[[@b10]\]. VDR expression in the brain was first evidenced by autoradiographic hormone-binding studies in the 1980s, together with the report that effects of sunlight or equivalent artificial light on behavioral processes could at least partially be mediated through vitamin D~3~-endocrine system \[[@b11], [@b12]\]. Prenatal vitamin D~3~ deficiency was demonstrated to impair brain development in rats \[[@b13]\] and cause subtle alterations in their learning and memory abilities \[[@b14]\]. Together with dexamethasone, vitamin D~3~ down-regulated microglial activation in the rat hippocampus, thus reversing various neuroinflammatory age-related changes \[[@b15]\]. Furthermore, a low vitamin D~3~ status is associated with low mood and impaired measures of cognitive performance in humans \[[@b16]\], and could possibly contribute to the aetiology of schizophrenia \[[@b17], [@b18]\]. Recent findings suggest that regular use of cod liver oil (major natural source of vitamin D~3~) decreases depressive symptoms in the general population \[[@b19]\]. In addition, genetic variance in the VDR gene apparently influences the susceptibility to age-related changes in cognitive functioning and in depressive symptoms \[[@b20]\].

Although there is growing evidence linking vitamin D~3~ levels to mental health \[21--[@b23]\], little is known about its direct effects, genetic targets and modes of action in the brain. With this study, we aimed to search for signalling pathways affected by vitamin D~3~ in the human CNS. As a model, we chose the human neuronal stem cell line HNSC.100, derived from a 10--10.5 weeks gestational age human Caucasian embryo and immortalized by v-myc expression \[[@b24]\]. These cells can be differentiated (by addition of CNTF) to up-regulate markers of three lineages (astrocytes ≥ 85%, neurons 10--15% and oligodendrocytes ≤ 1%; \[[@b24], [@b25]\]).

We first employed antibody microarrays (featuring over 600 different antibodies) to detect proteins that were changed in their expression and/or activation upon treatment with vitamin D~3~. The most prominent candidates were then further tested by Western blot analysis. Several structural and signalling targets of vitamin D~3~ were detected, with particularly strong up-regulation of PEA-15 (Phosphoprotein Enriched in Astrocytes-15 kD, also known as PED). This was highly interesting, because PEA-15 is a major phosphoprotein and an endogenous substrate for protein kinase C in astrocytes. It contains the death effector domain (DED) and is predominantly expressed in the central nervous system \[[@b26]\]. Among other functions, PEA-15 regulates the sub-cellular localization of ERK MAP kinase \[[@b27]\] and is linked to various anti-apoptotic and anti-proliferative effects \[[@b28]--[@b31]\]. For example, PEA-15 expression protected astrocytes from PEA-15 knockout mice from TNF-induced apoptosis \[[@b32]\] and transfection of PEA-15 cDNA in TRAIL (TNF-related apoptosis inducing ligand)--sensitive glioma cells rendered these cells resistant to TRAIL-induced apoptosis \[[@b33]\].

These important features of PEA-15 prompted us to characterize its up-regulation further and to examine the effects of vitamin D~3~ on processes known to be mediated by PEA-15, such as TRAIL-induced apoptosis. We revealed that **(***i*) the promoter of PEA-15 contains a conserved VDR response element, (*ii*) vitamin D~3~ leads to an up-regulation of the mRNA of PEA-15, which precedes the rise in protein level, (*iii*) vitamin D~3~ increases the level of phosphorylated PEA-15, possibly *via* AKT1, (*iv*) vitamin D~3~ treatment significantly rescued A549 cells from TRAIL-induced apoptosis and (*v*) this effect was strongly dependent on the presence of PEA-15, as revealed by RNAi experiments. In summary, this study provides insight into novel targets of vitamin D~3~ in HNSC.100 human brain cells and defines a novel pathway of vitamin D~3~ that counteracts apoptosis *via* up-regulation of PEA-15.

Materials and methods
=====================

Cell culture and treatments
---------------------------

The human neuronal stem cell line (HNSC.100) was propagated in DMEM:F-12 (1:1) medium supplemented with 0.5% FCS, 1% N2 (Invitrogen, Karlsruhe, Germany), 1% BSA (Sigma, Taufkirchen, Germant), 1% penicillin/streptomycin (Invitrogen) and human recombinant growth factors EGF and FGF-β (Tebu Biochem, Offenbach, Germany, 20 nM each). For differentiation, mitogens were removed and replaced with CNTF (100 nM) for 2--3 weeks. Differentiated HNSC.100 were treated for 24 hrs with ethanol vehicle (Sigma), or 10^−7^ M vitamin D~3~ (Biomol, Hamburg, Germany) and lysates prepared with ice-cold lysis buffer (20 mM MOPS, pH 7.2, 2 mM EGTA, 3.5 mM EDTA, 30 mM sodium fluoride, 60 mM glycerophosphate pH 7.2, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 3 mM benzamidine, 5 μM pepstatin A, 10 μM leupeptin, 1% Triton X-100).

Transfection and siRNA design
-----------------------------

To knock-down PEA-15, two siRNA duplexes were designed (21 nt double-stranded RNA containing 19 base pairs and 3' T- overhanging ends) using the Dharmacon siDesign Center software (UCACUAUGGUGGUUGACUATT and UGCAAGACCUGACCAACAATT, synthesized by Invitrogen). Transfections were performed with Lipofectamine according to the manufacturer's instructions (Gibco).

Antibody protein arrays
-----------------------

Over 600 antibodies (≥350 pan- and ≥280 phospho-site-specific, specification available upon request) were deposited in adjacent, duplicate spots on the glass slides (Kinexus Bioinformatics proprietary methodology). To ensure the most reliable comparison possible, both samples (control and treatment) were labelled with the same fluorescent dye (unlike DNA, proteins display strong individual differences in their relative affinities for dyes) and incubated on the same microarray (details available at <http://www.kinexus.ca>). Unbound dye-labelled lysate proteins were washed away and captured proteins quantified (Kinexus KAM-1.1 software). Analysis of the fluorescence signal strength for each target protein was provided in duplicates ([Table 3](#tbl3){ref-type="table"}) and includes the (average) percent change from the control sample, the percent range in error and fold-changes.

###### 

Selected protein targets for validation by conventional Western blot[\*](#tf3-1){ref-type="table-fn"}

  Protein name              %CFC
  ------------------------- --------
  CDK2                      101.83
  EGFR                      50.89
  GSK3a/b                   −61.19
  GSK3a/b (S21/S9)          −59.81
  GSK3a/b (Y279/ Y216)      −43.04
  MAPK14                    −18.77
  p38a MAPK (T180 + Y182)   −62.98
  PEA-15 (PED15) (S116)     953.61
  PI3K p110 delta           75.96
  PKA                       49.52
  PKBg (Akt3)               60.60
  PKCa                      59.75

In cases where the antibodies were directed against the phosphorylated form of the protein, the site of phosphorylation is given in parentheses after the protein name.

Western blot quantification
---------------------------

For validation, 500 μg of protein lysate derived from HNSC.100 was subjected to Western blot expression analysis. This analysis combines proprietary methodology (Kinexus Bioinformatics Corporation, Vancouver, BC, Canada) with analytical techniques, including SDS-PAGE gel electrophoresis, immunoblotting and enhanced chemoluminescence (ECL) protein visualization. First, proteins were separated by conventional gel electrophoresis based on their molecular weights, followed by detection with highly validated panel of human antibodies (the same as applied on the KAM1.1 chip).

Quantification of the bands was performed with a highly sensitive imaging system with a 16-bit camera in combination with the quantification software Immuno-Reactivity Identification System (IRIS) converting the light signals from the sample into digital data. From this, an intensity profile for the band is generated from summing each pixel's intensity for that band (only the bands whose clustered pixels were higher than the intensity of the pixels that make up the background of the image were considered for quantification). The raw data (a resulting trace quantity for each band scanned at the maximum scan time) was normalized to the average of all signals detected on the immunoblots of the screen. This was accomplished by summing the trace quantity of all the bands detected (known and unknown) on each immunoblot, finding the average total intensity per screen in any given normalization group, and then using a coefficient or scaling factor to multiply each trace quantity in each sample (this procedure helps to safeguard against inaccuracies in protein determination, protein loading and the inconsistencies as when normalizing the results to common internal references, which often vary significantly between samples). Therefore, the normalization was based on the same principle, but utilizing many proteins as references instead of one internal standard, possibly giving a more conservative estimate of the expression changes occurring. Data are listed as percent change from control (%CFC).

For the Western blots in [Figs 4](#fig04){ref-type="fig"}--[6](#fig06){ref-type="fig"}, cells were lysed as described earlier. Fifty micrograms of cell extract were resolved on 15% SDS--polyacrylamide and transferred to Hybond-C extra nitrocellulose. Membranes were blocked for 1 hr with 5% non-fat dry milk in TBS containing 0.05% Tween-20 incubated with primary antibodies (directed against: total AKT, pAKT (S473), total PEA-15, pPEA-15 (S116) and β-actin as indicated in the figures) and visualized by chemiluminescence \[[@b28]\].

![Conserved transcription factor binding sites in the promoter of PEA-15 and up-regulation of PEA-15 mRNA and protein. (A) Several transcription factor binding motifs were identified, including those for VDR, NFκB, EGRF, EKLF and SP1. (B) Effect of vitamin D~3~ on PEA-15 mRNA levels. A549 cells were treated with vitamin D~3~ (10^−7^ M), and the mRNA levels were determined by real-time PCR at the times indicated. (C) Verification of induction of total PEA-15 after 12 hrs by Western blot.](jcmm0013-3315-f4){#fig04}

![Effect of vitamin D~3~ on TRAIL-induced apoptosis and cell survival in A549 cells. (A) Cells were treated with vehicle, vitamin D~3~ and TRAIL in the combinations indicated. Metabolic activity (as a measure of cell viability and apoptosis \[FACS analysis\] were determined. (B) Same treatment as in (A), but in the presence of RNAi directed against PEA-15. Data represent mean values + S.E.M. of three independent experiments performed in triplicates each. Panel below (B), verification of the efficacy of the siRNA directed against PEA-15 by Western blot using an antibody detecting total PEA-15.](jcmm0013-3315-f5){#fig05}

![Effect of vitamin D~3~ on AKT and PEA-15. A549 cells were treated with vitamin D~3~ and harvested at the times indicated. Western blot analysis was performed to detect the levels of total AKT (AKT), phosphorylated AKT (pAKT), total PEA-15, (PEA15), phosphorylated PEA-15 (pPEA15) and β-actin as loading control.](jcmm0013-3315-f6){#fig06}

Real-time PCR
-------------

Total RNA was extracted from A549 cells using the TRIZOL reagent protocol (Invitrogen). Quality and quantity of the RNA were determined by measuring the absorbance at 260 and 280 nm, and by 1% agarose gel electrophoresis under denaturing conditions. RNA (1 μg) from each sample was reverse transcribed and one-step RT-PCR was performed by using SuperScript® III First-Strand system (Invitrogen) according to manufacturer's instructions. Primers for PEA-15 were 5′-GCAGTGCCTGGTTTAGCTTC-3′ (forward), 5′-TACGGGTTAGCTTGGTGTCC-3′ (reverse) and were synthesized commercially (PRIMM, Milan, Italy). Real-time PCR was performed by using iQ™ SYBR® Green Supermix (BIO-RAD, Munich, Germany). Reactions were performed in triplicate and β-Actin used as an internal reference cycling (conditions are available upon request).

Proliferation assays and cell death
-----------------------------------

Proliferation was evaluated with the CellTiter 96® AQ~ueous~ One Solution Cell Proliferation Assay (Promega, Madison, WI). A549 (lung carcinoma) cells (2 × 10^5^) were plated in 96-well plates (triplicates), stimulated with ligands and incubated at 37°C (at 5% CO~2~). Cell death was induced by using Super*Killer*TRAIL™ (Alexis Biochemicals, Lausanne, Switzerland) for 24 hrs at 100 ng/ml. Metabolically active cells were detected by adding 20 μl of methyl tetrazolium salt (MTS) to each well. After 2 hrs of incubation, the plates were analysed on a Multilabel Counter (BIO-RAD) according to the manufacturer's instructions. Apoptosis was measured by FACS (propidium iodide assay). The cells (2 × 10^5^) were washed with PBS and re-suspended in 200 μl buffer containing 0.1% sodium citrate, 0.1% Triton X-100 and 50 μg/ml propidium iodide (Sigma). Following incubation at 4°C for 30 min. in the dark, nuclei were analysed with a Becton Dickinson FACScan flow cytometer. Cellular debris was excluded from analyses by raising the forward scatter threshold, and the DNA content of the nuclei registered on a logarithmic scale.

Gene ontology sorting
---------------------

The Gene Ontology data annotation (version 161) <http://www.geneontology.org>; <http://www.ebi.ac.uk/GOA/>) was used to classify and characterize the genes that resulted from the antibody microarray analysis. Regulated genes were imported into BiblioSphere software (Version 7.13; Genomatix, Munich, Germany) and mapped to Gene Ontology (GO) trees in order to identify their biological function. In addition, the number of genes discovered as regulated by vitamin D~3~ in a certain class was related to the total number of genes to which antibodies were spotted on the chip.

Computational promoter analysis
-------------------------------

To identify conserved transcription factor binding sites for PEA-15, promoter sequences from three different species (*Homo sapiens*, *Mus musculus*, *Rattus norvegicus*) were first extracted by use of ElDorado program in the Genomatix software suite. The proximal promoter regions used were generally defined as about 500 nt upstream and 100 nt downstream of the transcriptional start side (TSS). Promoter sequences of the three different species were then compared by alignment with the help of DiAlign to evaluate overall promoter similarity. To find transcription factor--binding sites in the input sequences arranged by defined order, orientation and certain distance range between adjacent binding sites, the FrameWorker program (Genomatix) has been applied. For the promoter analysis position weight, matrices according to Matrix Family Library Version 7.0 (October 2007) were used.

Results
=======

Proteomic search indicates numerous targets of vitamin D~3~ in brain-derived cells
----------------------------------------------------------------------------------

To further elucidate the actions of vitamin D~3~ in human brain--derived cells, we started out by using antibody microarrays. They have the advantage of detecting the functional entity (protein) directly and also the added benefit of detecting protein isoforms, including in some cases phosphorylation isoforms. The antibody array used in our study (Kinexus) features more than 600 antibodies (≥350 pan-specific and ≥250 phospho-site-specific) deposited in duplicate spots.

As a model, we used the human neuronal stem cell line HNSC.100 \[[@b24]\]. Because of the sTable expression of v-myc, it can be perpetuated in the presence of the mitogens FGF-2 and EGF. Upon removal of the mitogens and in the presence of CNTF, cells undergo spontaneous morphological differentiation \[[@b24], [@b25]\]. After 2 weeks of differentiation, cultures were exposed to vitamin D~3~ for 24 hrs (10^−7^ M, [Fig. 1A](#fig01){ref-type="fig"}). Lysates of treated and untreated cells were then applied to the antibody array ([Fig. 1B](#fig01){ref-type="fig"}, complete list of antibody target proteins are referenced in supplementary Table 1).

![Procedure of the proteomic search for vitamin D~3~-regulated targets. HNSC.100 brain stem cells were cultivated and differentiated and treated with vitamin D~3~ for 24 hrs, and proteins were extracted from treated and untreated cells. After labelling proteins were bound to the antibody chips, which were then processed to yield candidate targets for further validation and characterization.](jcmm0013-3315-f1){#fig01}

More than 180 antibodies indicated altered expression and/or phosphorylation after vitamin D~3~ treatment, as compared with the vehicle-treated control ([Table 1](#tbl1){ref-type="table"}). Using Gene Ontology (GO, *via* BiblioSphere), we analysed regulated targets according to their functional classes and calculated, which percentage of proteins represented on the chip for any given category was regulated by the treatment. As summarized in [Table 2](#tbl2){ref-type="table"}, a high percentage of regulated proteins was found in the categories neuron development, neurogenesis, neurological processes and organelle organization and biogenesis (55.5%, 58.3%, 75.0% and 51.1% of the targets corresponding to the respective category). Like in the case of RNA microarrays, it is important to test some of these screening results by independent methods. Therefore, several candidates were selected ([Table 3](#tbl3){ref-type="table"}) according to their percentage change from the control (%CFC with respective error range) for validation by conventional Western blot.

###### 

List of vitamin D~3~-regulated proteins[\*](#tf1-1){ref-type="table-fn"}

  Protein name           %CFC     Protein name                %CFC     Protein name                   %CFC     Protein name            %CFC
  ---------------------- -------- --------------------------- -------- ------------------------------ -------- ----------------------- --------
  Abl (Y412)             48.39    JIK \[TAO3\]                −53.38   PKBa (Akt1) (S473)             −56.65   Rb (T821)               −47.07
  ACK1\[ACK\]            49.40    JNK                         −60.27   PKBa (Akt1) (S473)             1.37     Rb (T826)               −48.51
  AIF                    58.18    Jun (S63)                   −64.43   PKBa (Akt1) (S473)             47.91    Rb (S780)               −61.39
  Alk                    59.02    MAPKAPK2 (T222)             −48.57   PKBa (Akt1) (T308)             44.07    Ret (S696)              −50.89
  ANKRD3                 52.82    MEK1\[MAP2K1\] (T385)       160.80   PKBg (Akt3)                    60.60    RIPK                    −54.19
  Arrestin b1 (S412)     49.79    MEK7\[MAP2K7\]              39.93    PKBg (Akt3)                    104.38   Rb (T356)               −39.08
  ASK1\[MAP3K5\]         42.07    MEKK1\[MAP3K1\]             42.01    PKCa                           59.75    ROKa\[ROCK2\]           −52.16
  Bad (S99)              76.14    MKP1                        −37.80   PKCa/b2 (T638/T641)            −54.75   ROR2                    −41.76
  Bak                    69.32    Mnk1 (T209 + T214)          −52.98   PKCb2                          74.40    RSK2                    −43.86
  Bcl-xS/L               62.51    Mnk2                        −65.50   PKCd (S664)                    70.96    RSK1/2 (S380/S386)      78.34
  Bid                    68.12    Mos                         −44.47   PKCd (Y313)                    87.09    RSK1/2 (S221/S227)      −59.42
  Btk                    115.73   MRLC2 (S18)                 −49.26   PKCe (S729)                    111.75   RSK1/2 (S363/S369)      −41.89
  CAS                    69.55    Msk1 (S376)                 −69.50   PKCe (S729)                    55.77    RSK1/2 (S380/S386)      −44.83
  Catenin b              55.47    MST1                        −57.57   PKCg                           87.89    S6Ka \[p70 S6Ka\]       −42.53
  CDK2                   101.83   MST1                        −46.41   PKCg (T514)                    76.71    SIRPa1                  −42.01
  CDK1/2 (Y15)           104.61   MYPT1 (T696)                −48.44   PKCg (T674)                    79.58    STAT1 (S727)            −53.87
  CDK10                  92.90    Nek2                        −53.10   PKCq (S676)                    68.89    STAT1 (Y701)            −51.38
  Chk1                   68.90    Nek2                        −62.32   PKCq (S695)                    116.97   STAT3 (S727)            −45.76
  Crystallin aB (S19)    49.62    Nek2                        −50.27   PKD (PKCm)                     52.85    STI1                    41.78
  Crystallin aB (S45)    60.01    Nek7                        −49.49   PKD (PKCm) (S910)              −63.08   STK33                   85.79
  DNAPK                  56.89    NFkappaB p50                −44.64   PKM2                           62.55    Syk                     102.15
  Dok2 (Y142)            96.20    NFkB p65 (Rel A) (S276)     −47.40   PKN                            45.04    Synapsin 1 (S9)         79.19
  EGFR                   50.89    Nip1                        −46.25   Plk1                           72.54    TAK1                    25.86
  EGFR                   53.24    NME6                        −48.11   PP1/Ca (T320)                  56.56    Tau (S738)              59.37
  EGFR (Y1068)           53.23    NME7                        −53.78   PP2Cab                         45.78    Tau (S518)              25.20
  eIF2a (S51)            66.64    NR1 (S896)                  −68.80   PP5C                           94.37    Tau (S530)              58.44
  eIF2Be (S540)          61.39    p16 INK4                    −50.85   PP6C                           49.63    Tau (S578)              93.33
  Erk4                   −48.65   p18 INK4c                   −45.99   PRAS40 (T246)                  41.71    Tau (S712)              −50.11
  Erk6\[p38g\]           54.02    p35                         −41.17   PRK1/2\[PKN1/2\] (T774)        −53.59   Tau (T547)              64.83
  FAK (Y576)             54.89    p38a MAPK                   −48.49   PRKWNK4                        −53.20   TBK1                    127.12
  FAK (Y577)             −56.74   p38a MAPK (T180 + Y182)     −62.98   Progesterone Receptor (S294)   −50.71   Tlk1                    130.92
  GCK                    52.03    p53 (S392)                  −45.00   PTEN                           −51.11   TRADD                   95.57
  GFAP (S8)              −49.22   PAK1/2/3 (S144/S141/S154)   −52.47   PTEN (S370)                    −41.89   TrkA                    81.99
  GRK3\[BARK2\]          −35.17   PARP1                       −48.38   PTEN (S380 + S382 + S385)      −57.24   TTK                     105.00
  GSK3a/b (S21/S9)       −59.81   Pax2 (S394)                 −41.20   PTP1B                          −58.39   Tyk2                    78.70
  GSK3a/b (Y279/ Y216)   −43.04   Paxillin 1 (Y118)           −61.03   PTP1C                          −55.86   TH (S19)                122.06
  hHR23B                 −52.41   Paxillin 1 (Y118)           56.45    PTP1D                          −57.37   TH (S71)                73.38
  Histone H2A.X (S139)   −75.10   Paxillin 1 (Y31)            −47.29   PKR                            −43.59   VEGFR2\[KDR\] (Y1054)   62.03
  Hpk1                   58.84    PCTK1\[PCTAIRE1\]           −44.85   PTP-PEST                       −98.46   Vimentin (S33)          87.10
  Hsp27 (S78)            177.00   PDK1 (S244)                 −41.46   Pyk2 (Y579)                    −43.64   Vrk1                    117.51
  Hsp60                  133.04   PEA-15 (PED15) (S116)       953.61   Rad17 (S645)                   −53.78   Wee1                    44.52
  IKKa/b (S180)          −50.72   PI3K p110 delta             75.96    Raf1                           −51.29   XIAP                    55.94
  IKKb                   −56.26   PKA                         49.52    Rb (S612)                      −50.50   ZAP70 (Y315+Y319)       48.60
  IRAK4                  −50.42   PKA Cb (S338)               55.65    Rb (S807)                      −58.72   ZAP70 (Y319)            51.94
  JAK2                   −62.42   PKBa (Akt1) (T308)          75.72    Rb (S807 + S811)               −67.14   ZIPK                    44.78

Listed are the results of antibody microarray analysis (duplicate spots, complete list). In cases where the antibodies were directed against the phosphorylated form of the protein, the site of phosphorylation is given in parentheses after the protein name. %CFC, percent change from control.

###### 

Gene Ontology data sorting[\*](#tf2-1){ref-type="table-fn"}

  Gene ontology classes of vitamin D~3~ targets   Percentage of regulated proteins per GO class
  ----------------------------------------------- -----------------------------------------------
  Cell cycle                                      36.6
  Cell differentiation                            44.2
  Cellular development                            42.8
  Cellular communication                          38.8
  General regulation of biological processes      38.6
  Intracellular signalling cascade                40.1
  MAPKKK cascade                                  37.9
  NS development                                  41.9
  Phosphorylation                                 40.2
  Primary metabolic processes                     38.5
  Programmed cell death                           38.7
  Protein modification                            42.0
  Regulation of programmed cell death             32.9
  Response to stimulus                            42.5
  Signal transduction                             38.0
  Intracellular transport                         61.9
  Neurogenesis                                    58.3
  Neurological processes                          75.0
  Neuron development                              55.5
  Organelle organization and biogenesis           51.1

Results of the antibody array were sorted using Gene Ontology (<http://www.geneontology.org>, <http://www.ebi.ac.uk/GOA/>). The percentage of regulated proteins was calculated as the proportion of affected proteins from the total number of proteins for the given category.

Western blot validation
-----------------------

Independent samples of differentiated HNSC.100 cells were lysed in SDS-PAGE sample buffer as described (Materials and Methods) and resolved on a SDS-PAGE gel followed by electrophoretic transfer to a nitrocellulose membrane. Membranes were probed with antibodies identical to those used on the protein array (Kinexus), visualized with the ECL detection system and quantified by using IRIS identification software ([Fig. 2](#fig02){ref-type="fig"}). For approximately 40% of examined targets, changes measured by the antibody microarray could be reproduced by Western blot, such as CDK1/2, EGFR, PKA, Akt3 and PKCα. GSK3α/β yielded partially conflicting results (down-regulated −59.8% and −43.04% on the array and −28% and −10% on Western blot), as well as PI3K/p100 delta (up-regulated 75.9% on the array and down-regulated 17% in the Western blot). Notably, the phosphorylated form of PEA-15 remained the most strongly vitamin D~3~-regulated protein after the Western blot validation ([Figs 2](#fig02){ref-type="fig"} and [3](#fig03){ref-type="fig"}). This confirms the responsiveness of PEA-15 to vitamin D~3~, although the two methods indicated different degrees of up-regulation (953% antibody array *versus* 268% Western blot up-regulation).

![Western blot testing of candidate targets of vitamin D~3~. Differentiated HNSC.100 cells were treated with vitamin D~3~ or vehicle for 24 hrs, and Western blots were performed with cell lysates.](jcmm0013-3315-f2){#fig02}

![Quantification of the changes in protein level induced by vitamin D~3~ for the selected proteins. Quantification of the bands shown in [Fig. 2](#fig02){ref-type="fig"} was performed with an imaging system in combination with the quantification software IRIS (Immuno-Reactivity Identification System, see Materials and Methods).](jcmm0013-3315-f3){#fig03}

PEA-15 promoter analysis and mRNA induction by vitamin D~3~
-----------------------------------------------------------

Given the strong response of PEA-15 to vitamin D~3~ indicated by two independent samples/methods and its prominent expression in the CNS (particularly abundant in astrocytes \[[@b31]\]), we focussed our further experiments on this candidate. First, we searched by bioinformatics tools for VDR-binding sites in the PEA-15 promoter of the human, mouse and rat genomes. The sequence upstream of the transcription site contains several transcription factor binding motifs, including those for NFκB, EGRF, EKLF and SP1 ([Fig. 4A](#fig04){ref-type="fig"}). One of these sites is conserved between human, mouse and rat promoter, thus strongly indicating a functional vitamin D~3~-- dependency of the PEA-15 gene promoter.

To experimentally test the up-regulation of the PEA-15 gene promoter by vitamin D~3~, we treated cells with vitamin D~3~ and measured the mRNA of PEA-15 by real-time PCR. We observed indeed a rise of the PEA-15 mRNA already after 3 and 6 hrs ([Fig. 4B](#fig04){ref-type="fig"}). Using an antibody that recognizes PEA-15 irrespective of its phosphorylation status we also detected an up-regulation of the total amount of PEA protein after 12 hrs ([Fig. 4C](#fig04){ref-type="fig"}).

Vitamin D~3~ regulates PEA-15 function
--------------------------------------

We next investigated whether the effect of vitamin D~3~ on PEA-15 expression changes cellular processes that depend on the function of PEA-15. Numerous studies suggest the involvement of PEA-15 in a broad range of anti-apoptotic processes in cultured cells \[[@b32]--[@b35]\]. TRAIL (tumour necrosis factor apoptosis-inducing ligand) is an efficient inducer of apoptosis and in TRAIL-sensitive cells; transfection of PEA-15 cDNA resulted in cell resistance, whereas inhibition of PEA-15 expression changed the TRAIL-resistant phenotype to sensitive \[[@b29], [@b33]\]. Given that normal astrocytes are generally TRAIL-resistant \[[@b33]\], we chose the TRAIL-sensitive cell line A549 to examine VDR and PEA-15 expression in the presence and absence of vitamin D~3~.

First, we verified by Western blot that A549 cells express VDR, indeed (data not shown). To test whether vitamin D~3~ influences TRAIL-induced apoptosis, we pre-treated A549 cells with vitamin D~3~ (10^−7^ M, as in the previous experiments) for 12 hrs before apoptosis was induced with TRAIL (100 ng/ml for the next 24 hrs). Cell nuclei were visualized with propidium iodide and subjected to FACS analysis to monitor late-stage apoptosis, and MTS proliferation assays were performed to measure cell viability. Treatment with vitamin D~3~ alone did not have a significant effect on apoptosis, as compared with vehicle-treated cells ([Fig. 5A](#fig05){ref-type="fig"}, right panel, grey bar), whereas treatment with TRAIL resulted in approximately 50% apoptotic cells, as expected ([Fig. 5A](#fig05){ref-type="fig"}, right panel, black bar). Notably, cells pre-treated with vitamin D~3~ prior to TRAIL administration exhibited markedly decreased levels of TRAIL-induced apoptosis ([Fig. 5A](#fig05){ref-type="fig"}, right panel, dark grey bar). MTS assays paralleled the observed changes, indicating that a decrease in cell proliferation/viability induced by TRAIL could be significantly reverted by pre-treating cells with vitamin D~3~ ([Fig. 5A](#fig05){ref-type="fig"}, left panel).

To answer the crucial question of whether the effect of vitamin D~3~ is dependent on PEA-15, we silenced the PEA-15 gene with siPEA RNA, prior to treating cells with vitamin D~3~ and TRAIL (reduced PEA-15 expression level are documented below the graphs of [Fig. 5B](#fig05){ref-type="fig"}). Interestingly, the attenuating effect of vitamin D~3~ on the actions of TRAIL in apoptosis and cell viability was completely abolished in PEA-15 silenced cells ([Fig. 5B](#fig05){ref-type="fig"}, dark grey bars). These data suggest that PEA-15 is mediating the effects of vitamin D~3~ in cell survival.

Vitamin D~3~ increases phosphorylation of AKT1 and PEA-15
---------------------------------------------------------

The strong up-regulation observed using an antibody directed against PEA-15 phosphorylated at serine 116 raised the question of whether the increase in the level of total protein is achieved in part by increasing protein stability. It has been reported that PEA-15 is phosphorylated by protein kinase Bα/AKT1, which leads to stabilization of the protein \[[@b36]\]. Therefore, we used Western blot analysis to measure the levels of phosphorylated AKT1, total AKT1, phosphorylated PEA-15 and total PEA-15 after treatment of the cells with vitamin D~3~. Phosphorylation of AKT1 is a measure of the activity of this kinase \[[@b37]\]. We observed an activation of AKT1 3 and 6 hrs after addition of vitamin D~3~, whereas the level of total AKT1 protein was unchanged ([Fig. 6](#fig06){ref-type="fig"}). Interestingly, 6 hrs after addition of vitamin D~3~, we found an increase in phosphorylation of PEA-15 but no change in the level of total PEA-15 yet ([Fig. 6](#fig06){ref-type="fig"}), which rises only after 12 hrs ([Fig. 4](#fig04){ref-type="fig"}). These data support the view that vitamin D~3~ uses two mechanisms to increase the function of PEA-15, stimulation of gene transcription and stabilization of the protein through phosphorylation, possibly *via* activation of AKT1.

Discussion
==========

In this study we searched for vitamin D~3~-regulated targets in the proteome of human brain--derived cells. Several expression changes indicated by the antibody array paralleled the ones described previously by other authors. Among them are up-regulation of EGFR \[[@b38]--[@b40]\], down-regulation of activated p38 MAPK \[[@b41]\], up-regulation of tyrosine hydroxylase \[[@b42]\] and down-regulation of GSK3β mRNA in differentiated HIB5 rat hippocampal cells (own unpublished observations). Although this congruence with other published data in general attests to the reliability of the array, we also observed inconsistencies for some of the proteins examined on the array, for example, AKT1 or paxillin 1. We do not know whether the reason for this is accidental variation or due to unknown differences in the spotted antibodies, which are supposed to recognize the same modified protein. In any case, this reinforces the notion that results of screening methods such as mRNA or protein microarrays should be validated by independent methods.

Up-regulation of PEA-15 was the most prominent feature on the antibody array. We investigated this up-regulation further and conclude from our experiments with different cell lines that vitamin D~3~ leads to an increase in promoter activity of PEA-15 already after 3--6 hrs ([Fig. 4B](#fig04){ref-type="fig"}), and with a little delay to an increase in protein phosphorylation after 6 hrs ([Fig. 6](#fig06){ref-type="fig"}), most likely *via* activation of AKT1, which is known to phosphorylate PEA-15 \[[@b36]\]. The increase in mRNA and the protein stabilization through phosphorylation in combination lead to an increase in total PEA-15 protein level after 12 hrs ([Fig. 4B](#fig04){ref-type="fig"}). On the microarray, five antibodies were directed against activated (*i.e.* phosphorylated) AKT1. Most of them actually indicated the increased activation of AKT1, but one of them detected less phosphorylated AKT1 (see paragraph above).

A bioinformatics search revealed a conserved VDR-binding site in the promoter of PEA-15, in line with a direct regulation of the promoter activity by VDR. In addition, we identified a conserved Sp1 binding site. Considering the finding of a functional VDR/SP1 complex \[[@b43]\], this SP1 site could contribute further to the VDR dependency of PEA-15. PEA-15 is also on the list of about 50 differentially expressed genes in the mouse brain revealed by two-dimensional gel electrophoresis in a model of developmental vitamin D deficiency \[[@b44]\]. Although this finding was not discussed or followed-up, it is in line with the vitamin D dependency of PEA-15 outlined in our study.

Significant knowledge about the function of PEA-15 has already been accumulated, such as its anti-apoptotic and anti-proliferation features \[[@b32], [@b34], [@b45], [@b46]\]. The interaction of PEA-15 with DED containing molecules such as FADD and caspase-8 in the death inducing signalling complex is considered to play an important role in the inhibition of cell death--induced activation of TNFR1 \[[@b45]\]. The mechanism of the anti-proliferative action of PEA-15 involves binding to the extracellular signal receptor-activated kinases (ERK1/2) and their export out of the nucleus \[[@b47]\]. This shift of ERK activity from nuclear to cytosolic targets then results in attenuated cell proliferation \[[@b46]\]. Our finding of increased AKT1 activity after vitamin D~3~ exposure not only provides a potential mechanism for activation of PEA-15 but also adds another pathway through which vitamin D~3~ exerts anti-apoptotic effects. AKT1 has been established as a central node promoting cell survival downstream of growth factors, oncogenes and cell stress \[[@b48]\].

Important for understanding the function of PEA-15 in the brain was its immunohistochemical mapping in the mouse brain \[[@b31]\]. Although early *in vitro* studies suggested its expression mainly in astrocytes \[[@b26]\], immunostaining revealed that PEA-15 was expressed in defined astrocyte sub-populations as well as neurons throughout the brain \[[@b31]\]. Interestingly, it is also expressed in areas known for neurogenesis in the murine embryonic and adult brain \[[@b31], [@b49], [@b50]\]. Therefore, vitamin D~3~ impact on PEA-15 expression and function described in this study may be important in this context to contain further proliferation and allow differentiation.

Our discovery that PEA-15 is strongly responsive to vitamin D~3~ potentially links vitamin D~3~ to any of the actions of PEA-15. Although extensive work needs to be done to test the degree of overlapping activities, we already showed in this work that vitamin D~3~ significantly affected apoptosis and cell survival in A549 cells in a PEA-15-dependent manner. The differentiation-inducing and anti-proliferative effects of vitamin D~3~ in various tissues are well described \[[@b51]--[@b54]\]. Therefore, we propose that the pathway revealed in this study contributes to these effects and constitutes the molecular basis for these actions of vitamin D~3~. This probably also applies to the positive effects of vitamin D~3~ in cancer \[[@b55], [@b56]\], most recently highlighted by a widely noticed study outlining positive effects of sun exposure *via* improving the vitamin D~3~ status \[[@b57]\].

Since VDR activity was reported to be induced by stress \[[@b58]\], it is tempting to speculate that up-regulation of PEA-15 by VDR plays a role in the stress response in the brain. It could, for example, contribute to the suppression of neurogenesis by stress \[[@b59]\] as well as counteracting the damage stress is executing on some brain cells \[[@b60]\], in particular because PEA-15 is found in brain areas sensitive to stress \[[@b61]\]. In this respect, it is interesting to note that in the ventral tegmental area AKT1, another target of vitamin D~3~ we could confirm in this study, has very recently been shown to be involved in the regulation of vulnerability to social defeat and of depression-related behaviours in rats \[[@b62]\].

With respect to brain function in general, numerous studies indicated the importance of regulating apoptosis for normal brain development and function \[[@b63], [@b64]\]. Thus, the positive role of vitamin D~3~ reported for brain development \[[@b22], [@b65]\] and mental health \[[@b16], [@b20]\] may operate at least in part through its effect on apoptosis *via* inducing PEA-15.
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